Global biotechnology company BioCryst Pharmaceuticals Inc. (BCRX) is approaching an indispensable regulatory moment with the FDA expected to deliver its decision on December 12, 2025, regarding the approval of ORLADEYO Oral Granules for pediatric patients aged 2 to 11 years with hereditary angioedema (HAE). Much Hinges On The FDA's VerdictThe oral granule formulation is a pediatric extension of Bi...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.